ISSN:
1569-8041
Keywords:
lymphoma
;
positron emission tomography
;
residual mass
;
18-fluorodeoxyglucose (FDG)
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Background: PET using 18fluorodesoxyglucose (FDG) mayoffer the possibility of differentiating vital from necrotic residual masses. Patients and methods: Seventeen patients with HD and 17 patients withNHL underwent FDG-PET following therapy. According to staging by routinemethods at diagnosis, 7 patients presented stage I, 13 stage II, 5 stage III,and 9 stage IV. A dose of 250–400 MBq FDG was injected and whole-bodyPET was performed 30–60 minutes later. Results: Residual mass was found in 32 patients with routine methods.FDG-PET was negative in 17 patients, who were considered to be in CR. None ofthem relapsed (median follow-up 63 weeks). FDG-PET was positive in 17patients. Sixteen patients had residual mass with routine methods. Fourpatients received radiation after PET. Their median follow-up is 58 weekswithout relapse. Two other patients with lasting CR had FDG uptake outside theresidual mass – one with confirmed pneumonia. Five patients hadhistologically confirmed lymphoma, 2 patients relapsed according to routinemethods. One patient is likely to be false positive because of fracture atlymphoma site. Seven of 10 patients with FDG uptake in the residual mass aftercompleted therapy relapsed. According to routine restaging, 2 patientsachieved CR. In 1 patient an additional focus was found in the humerus inspite of normal scintigraphy with histologically confirmed lymphoma. Therewere no false-negative results, but 3 false-positive results inside and 2false-positive results outside the residual mass after completed therapy. Conclusion: PET performed for evaluation of residual mass aftertreatment of lymphoma has a high predictive value.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1023/A:1008253917337
Permalink